80,985 Shares in Amgen Inc. $AMGN Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 80,985 shares of the medical research company’s stock, valued at approximately $29,326,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. California State Teachers Retirement System increased its position in shares of Amgen by 36,047.1% in the second quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company’s stock worth $108,004,388,000 after acquiring an additional 297,430,677 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. State Street Corp lifted its holdings in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors boosted its position in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Finally, Geode Capital Management LLC boosted its position in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AMGN shares. Truist Financial increased their price target on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Daiwa Securities Group reduced their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Scotiabank upped their target price on Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. TD Cowen increased their target price on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Bank of America raised their target price on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $381.68.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen continues to be viewed as a long-term growth candidate, supported by its diversified drug portfolio and potential pipeline contributions. However, the bullish commentary is largely based on broad fundamental and valuation screens rather than a new company-specific announcement. Why Amgen Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: An industry report identified Amgen, Roche and Johnson & Johnson as leading participants in the expanding oncology bi/multispecific-drug market. The report offers sector context but does not announce a new Amgen asset, deal or clinical result, so its immediate effect on AMGN is likely limited. Bi/Multispecific Oncology Market Report
• Neutral Sentiment: Congressman David Taylor disclosed several trades, including sales of biotech holdings. These transactions are not directly linked to Amgen’s operations or outlook and do not provide a meaningful fundamental signal for AMGN. Congressional Stock Trades
• Negative Sentiment: Novartis reported that its Phase III pelacarsen study failed to reduce cardiovascular events, despite testing a lower target biomarker level. Investors are concerned that the result may challenge the broader “lipoprotein(a)” treatment mechanism and make it harder for Amgen’s 7,297-patient olpasiran outcome trial to produce a positive result. Amgen Shares Fall as Pelacarsen Misses Phase III Goal
• Negative Sentiment: The pelacarsen failure prompted a pullback in Amgen shares as investors reassessed olpasiran’s probability of success and potential commercial value. The concern is currently a pipeline-risk repricing, not evidence that Amgen’s approved products or recent earnings performance have deteriorated. Amgen’s 7,297-Patient Heart Bet Inherited a Higher Bar

Amgen Stock Performance

Amgen stock opened at $437.23 on Tuesday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $236.38 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The firm’s fifty day moving average price is $398.92 and its 200 day moving average price is $367.59.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts forecast that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s payout ratio is 62.65%.

Insider Activity

In related news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.